Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Marwan Fakih, Lisa Salvatore, Taito Esaki, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 23, pp. 2125-2139
Closed Access | Times Cited: 157

Showing 26-50 of 157 citing articles:

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers
Robin A. Jansen, Sara Mainardi, Matheus Henrique Dias, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 9
Open Access | Times Cited: 6
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Huanhuan Yin, Qiulin Tang, Hongwei Xia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1895-1923
Open Access | Times Cited: 6
Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases
Marco Tonello, Dario Baratti, Paolo Sammartino, et al.
ESMO Open (2024) Vol. 9, Iss. 4, pp. 102976-102976
Open Access | Times Cited: 6
Impact of Systemic Treatments on Outcomes and Quality of Life in Patients with RAS-Positive Stage IV Colorectal Cancer: A Systematic Review
Vlad Braicu, S. Pantea, Fulger Lazăr, et al.
Diseases (2024) Vol. 12, Iss. 4, pp. 79-79
Open Access | Times Cited: 6
Metabolic Response to Small Molecule Therapy in Colorectal Cancer Tracked with Raman Spectroscopy and Metabolomics
Gabriel Cutshaw, Neeraj Joshi, Xiaona Wen, et al.
Angewandte Chemie International Edition (2024)
Closed Access | Times Cited: 6
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions
David Johnson, Cheng Ean Chee, Wesley P. Wong, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102700-102700
Closed Access | Times Cited: 5
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Jing Zhang, Sun Min Lim, Mi Ra Yu, et al.
Cancer Discovery (2024) Vol. 14, Iss. 9, pp. 1675-1698
Open Access | Times Cited: 5
Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine
İbrahim Halil Şahin, Turçin Saridogan, Rüveyda Ayasun, et al.
JCO Oncology Practice (2024) Vol. 20, Iss. 10, pp. 1336-1347
Closed Access | Times Cited: 5
Advances in Personalized Oncology
Hiba Mechahougui, James Gutmans, Gina Colarusso, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2862-2862
Open Access | Times Cited: 5
Impact of Sotorasib, a KRAS G12C Inhibitor, on the Pharmacokinetics and Therapeutic Window of Digoxin, a P‐Glycoprotein Substrate
Panli Cardona, Brett E. Houk
Clinical Pharmacology in Drug Development (2025)
Closed Access
Impact of HIF-1α, LOX and ITGA5 Synergistic Interaction in the Tumor Microenvironment on Colorectal Cancer Prognosis
Hayriye Tatlı Doğan, Mehmet Doğan, Seda Kahraman, et al.
Diagnostics (2025) Vol. 15, Iss. 2, pp. 184-184
Open Access
Understanding colorectal cancer, screening, and treatment
Mohan Krishna Ghanta, Mohammad Enayet Hussain, Subrahmanya Narayan Dora Kurumella, et al.
Elsevier eBooks (2025), pp. 167-189
Closed Access
Gene Editing in ErbB/HER Family-Mediated Cancer Immunology
Ling Yin
IntechOpen eBooks (2025)
Closed Access
Chaperone Directed Heterobifunctional Molecules Circumvent Krasg12c Inhibitor Resistance
Takeshi Shimamura, Inés Pulido, Qiyue Luan, et al.
(2025)
Closed Access
Colorectal Cancer: Current and Future Therapeutic Approaches and Related Technologies Addressing Multidrug Against Multiple Level Resistance Mechanisms
Marianna Puzzo, Marzia De Santo, Catia Morelli, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1313-1313
Open Access
Molecular features and clinical actionability of gene fusions in colorectal cancer
Francesco Giulio Sullo, Simon Garinet, Hélène Blons, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104656-104656
Closed Access
STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
Zehao Pan, Yuxian Qian, Yajing Wang, et al.
Cancer Science (2025)
Open Access
Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets
Zhaohui Arter, Alexandria TM Lee, Misako Nagasaka, et al.
Cancer Medicine (2025) Vol. 14, Iss. 4
Open Access
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Peiyuan Yang, Yongchao Li
Investigational New Drugs (2025)
Closed Access
Therapiekonzepte sowie Prävention/Überwindung von Resistenzen
Alexander Kretzschmar
Onkologische Welt (2025) Vol. 16, Iss. 01, pp. 6-7
Closed Access
Disitamab vedotin combined with pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report
Jianxin Chen, Jian Wang, Qinhong Zheng
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Global alliances in translational cancer research
Hui Luo, Yun‐Xin Lu, Kohei Shitara, et al.
Cancer Cell (2025)
Closed Access
The Pharmacologic inhibition of KRAS mutants as a treatment for cancer: Therapeutic principles and clinical results
Stefan Kasper, Martin Sebastian
Deutsches Ärzteblatt international (2025)
Closed Access

Scroll to top